Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-59R5 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Mereo BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of **OMP-59R5 (tarextumab)**, **gemcitabine**, and **nab-paclitaxel** evaluated for the treatment of previously untreated stage IV pancreatic cancer. OMP-59R5 (tarextumab) is a fully human IgG2 monoclonal antibody that inhibits the Notch2 and Notch3 receptors, disrupting Notch signaling important for cancer stem cells and tumor progression. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel that stabilizes microtubules, thereby inhibiting cell division. This combination has been studied in randomized phase 1b/2 clinical trials, with evidence of anti-tumor efficacy, particularly in patients with higher tumor Notch3 expression[1][2][3][5][7][8].
- Other names
- OMP-59R5 + gemcitabine + nab-paclitaxeltarextumab + gemcitabine + nab-paclitaxel
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on OMP-59R5 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-59R5 + gemcitabine + nab-paclitaxel.